News

This patent broadly covers the use of the URG101 product in the treatment of painful bladder syndrome or interstitial cystitis (PBS/IC). The term of the patent extends into

Based on the performance of its EP-vCJD assay, Amorfix received and accepted an invitation from the British government to further qualify the specificity of the assay using British

The newly launched test complements a larger personalized medicine portfolio which includes, subject to regulatory approval in various countries, molecular tests related to transplantation, cancer and other therapies.

According to the company, the Dynabeads Max Legionella provides a rapid and highly reliable sample preparation process, improving the method used, and result achieved, for the detection and

The trial will be conducted in the US and EU and will enroll approximately 650 genotype 1 hepatitis C virus (HCV) patients who failed prior treatment with pegylated-interferon

In this newly created position, Dr Tapolsky will be responsible for the leadership of all preclinical and clinical development activities. Prior to joining Advanced Cancer Therapeutics, Dr Tapolsky

Cellumen is focused on decreasing the drug attrition rate due to toxicity. The company’s CellCiphr CSB toxicity profiling services can identify toxic compounds in late primary screening through

Preclinical testing has indicated that these insulin receptor activators, as single agents, lower glucose levels in models of diabetes. The compounds are active in the presence of sub-maximal

Melior is using theraTRACE to both build an internal pipeline of development candidates as well as sharing this capability with pharmaceutical and biotechnology company partners. Andrew Reaume, president